Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. reports developments in commercial-stage cancer prevention diagnostics for patients with gastroesophageal reflux disease who are at risk for esophageal precancer and esophageal adenocarcinoma. The company, a subsidiary of PAVmed Inc., markets the EsoGuard Esophageal DNA Test and uses the EsoCheck Esophageal Cell Collection Device to collect samples through a brief, noninvasive office procedure.
Recurring updates cover EsoGuard commercialization, healthcare-system access, clinical evidence for esophageal precancer detection, quarterly business results, cash resources, and conference presentations. Lucid news also includes capital actions such as registered common stock offerings and related use of proceeds for working capital and general corporate purposes.
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced that its EsoGuard® Esophageal DNA Test for early detection of esophageal precancer will be highlighted at the American Foregut Society's (AFS) 2024 Annual Meeting from September 26-28, 2024. Dr. Dan Lister, AFS President-elect, will lead a session titled "Finding Barrett's - Time to Ditch the Scope?" discussing EsoGuard as a non-invasive alternative to screening upper endoscopy.
This follows the AFS's recent open letter advocating for medical policy coverage of EsoGuard by commercial payors, emphasizing its strong scientific evidence and incorporation in AFS physicians' practices. The session will explore EsoGuard's role in triaging at-risk patients and enabling efficient use of endoscopy resources for early detection and prevention of esophageal cancer.
PAVmed Inc. (Nasdaq: PAVM) announced efforts to regain compliance with Nasdaq's listing requirements, including the deconsolidation of Lucid Diagnostics (Nasdaq: LUCD) from PAVmed's financial statements. This move will no longer reflect Lucid's operating losses in PAVmed's consolidated financials, while maintaining PAVmed's holdings of Lucid common stock. The deconsolidation is part of a series of steps to address Nasdaq's determination that PAVmed had not met continued listing standards for 180 consecutive days.
PAVmed also announced board changes, including the appointment of Dr. Sundeep Agrawal, a seasoned biotech investor, to replace departing directors. The company will request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination, expected in October.
Lucid Diagnostics (Nasdaq: LUCD) announced its participation as the sole Diamond Sponsor at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress in Edinburgh, Scotland, from September 22-24, 2024. The company will showcase its EsoGuard® Esophageal DNA Test for early detection of esophageal precancer.
Lucid will host a symposium on Non-Endoscopic Screening for Barrett's Esophagus, chaired by experts Dr. Vani Konda and Dr. Nicholas Shaheen. The panel discussion will include Dr. Vivek Kaul and Dr. Rehan Haidry. This event highlights Lucid's commitment to being a leading voice in esophageal cancer prevention through early detection of precancer.
The ISDE World Congress is a global platform for collaboration and knowledge exchange among experts in esophageal diseases, covering topics such as diagnostics, novel therapies, and latest advancements in the field.
Lucid Diagnostics (Nasdaq: LUCD) has signed a memorandum of understanding (MOU) with Front Line Mobile Health to enhance early detection of esophageal cancer in firefighters. The collaboration aims to expand patient access to Lucid's EsoGuard® Esophageal DNA test through co-marketing initiatives. Firefighters face a 62% higher risk of developing esophageal cancer, making this partnership important for their health and safety.
The MOU builds on Lucid's previous collaboration with Front Line, which facilitated a major #CheckYourFoodTube Precancer Testing Event. By leveraging Front Line's resources and expertise in caring for firefighters, Lucid aims to increase access to esophageal precancer testing and drive revenue through contracted high-volume testing events.
Lucid Diagnostics, a subsidiary of PAVmed, has published an analytical validation study of its EsoGuard® Esophageal DNA test in the peer-reviewed journal Diagnostics. The study demonstrates excellent analytical performance of the EsoGuard assay on samples collected with the EsoCheck® Esophageal Cell Collection Device for diagnosing esophageal precancer (Barrett's Esophagus) and esophageal adenocarcinoma.
Key findings include:
- 89% analytical sensitivity
- 100% analytical specificity
- 96% analytical accuracy
- 100% inter- and intra-assay precision
EsoGuard uses next-generation sequencing to detect DNA methylation at 31 sites on two genes associated with conditions along the BE-EAC spectrum. This study complements EsoGuard's existing clinical validity and utility evidence base.
The American Foregut Society (AFS) has formally requested health insurance providers to update their medical policies to include Lucid Diagnostics' (Nasdaq: LUCD) EsoGuard® Esophageal DNA test as a covered service. This move aims to enhance early detection of esophageal precancer (Barrett's Esophagus) and prevent highly lethal esophageal cancer. The AFS, a leading society of gastroenterologists and surgeons, highlighted the strong scientific evidence supporting EsoGuard as a minimally invasive screening alternative to endoscopy.
The AFS emphasized that expanding access to EsoGuard will empower providers with an essential triage for upper endoscopy, enabling early detection of Barrett's Esophagus. As a point-of-care test in primary care offices, EsoGuard can reduce health disparities in endoscopy access. The society urged immediate coverage of the test, aligning with recent gastroenterology society guidelines and state legislation mandating coverage of such biomarker tests.
PAVmed Inc. (NASDAQ: PAVM) provided a business update and Q2 2024 financial results. Key highlights include:
- Lucid reported record quarterly EsoGuard® test volume of 3,147, up 31% from Q1
- EsoGuard revenue was $1.0 million, up 514% year-over-year
- Veris Health launched a pilot program with The Ohio State's James Cancer Hospital
- Q2 operating expenses were $14.6 million
- GAAP net loss was $10.9 million or $(1.19) per share
- Non-GAAP adjusted loss was $7.7 million or $(0.84) per share
- Cash and equivalents of $25.5 million as of June 30, 2024
The company is focused on strengthening finances by making subsidiaries independently financeable. Lucid remains PAVmed's strongest asset, while Veris Health and PortIO are pursuing independent financing.
Lucid Diagnostics Inc. (NASDAQ: LUCD) reported its Q2 2024 financial results and business update. Key highlights include:
- EsoGuard® test volume increased 31% quarterly and 44% annually
- EsoGuard revenue was $1.0M, flat compared to Q1 but up 514% year-over-year
- 3,147 commercial EsoGuard tests performed, a single-quarter record
- Positive clinical data released from ENVET-BE and ESOGUARD BE-1 studies
- Cash and cash equivalents of $24.9M as of June 30, 2024
- GAAP net loss of $11.0M or $(0.23) per share
- Non-GAAP adjusted loss of $9.7M or $(0.20) per share
The company is focused on securing broad coverage and reimbursement to drive EsoGuard revenue growth.
Lucid Diagnostics (Nasdaq: LUCD) successfully completed its first major directly-contracted #CheckYourFoodTube Precancer Testing Event in partnership with the Fort Worth Fire Department (FWFD) and Front Line Mobile Health. Nearly 200 firefighters underwent testing using Lucid's EsoGuard® Esophageal DNA test and EsoCheck® Esophageal Cell Collection Device.
FWFD Fire Chief Jim Davis emphasized the importance of early detection, citing his personal loss to esophageal cancer. Lucid's President and COO, Shaun O'Neil, highlighted the potential for directly contracting with self-insured entities to contribute to long-term revenue growth. The event garnered local media coverage and addressed the increased risk of esophageal cancer among firefighters.
Lucid Diagnostics (Nasdaq: LUCD) has released new real-world data from its ENVET-BE study, demonstrating the clinical utility of the EsoGuard® Esophageal DNA test as a non-invasive triage tool for detecting esophageal precancer and cancer. The study showed that patients triaged to invasive upper endoscopy (EGD) following a positive EsoGuard test had a 2.4-fold increase in positive yield compared to screening EGD alone in at-risk patients.
Key findings include:
- EGD confirmed Barrett's Esophagus (BE) in 50 out of 199 patients who received a positive EsoGuard result
- Post-triage EGD yield was 25%, compared to the expected 11% yield of EGD as a standalone screening tool
- Results support the use of EsoGuard as an alternative to EGD for esophageal precancer testing, potentially increasing compliance with screening guidelines and reducing esophageal cancer deaths